Xiamen Amoytop Biotech Hits Day High with Strong 3.29% Intraday Surge

Xiamen Amoytop Biotech Co. has experienced a notable increase of 3.29% on February 25, 2026, reaching an intraday high of CNY 76.71. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 1.26% on the same day. Over the past week, Xiamen Amoytop has shown a robust gain of 5.73%, while the monthly performance reflects a modest increase of 0.87%. Despite a challenging year, where the stock has seen a decline of 9.63%, the company has consistently reported positive results for the last 18 consecutive quarters. Key financial metrics indicate a strong operational performance, with net sales reaching a record CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company boasts a return on equity of 34.50% and a price-to-book ratio of 12.11, suggesting a fair valuation in the current market context. With a market capitalization of CNY 29,448 million, Xiamen Amoytop continues to be a significant player in the pharmaceuticals and biotechnology sector, demonstrating resilience amid market fluctuations.